I. Diel

R. Ziegler, J. Pfeilschifter, I. Diel, 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Intravenous pamidronate versus oral and intravenous clodronate in bone metastatic breast cancer: a randomized, open-label, non-inferiority Phase III trial

A. Schneeweiss, M. Golatta, F. Schuetz, 2016, OncoTargets and therapy.

Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells.

G Kvalheim, J. Nesland, B. Naume, 1999, Cytotherapy.

COMMENT ON : MICROMETASTATIC BREAST CANCER CELLS IN BONE MARROW AT PRIMARYSURGERY : PROGNOSTIC VALUE IN COMPARISON WITH NODAL STATUS. AUTHORS' REPLY

S. Braun, F. Hepp, K. Pantel, 1998 .

Cognate interactions between memory T cells and tumor antigen‐presenting dendritic cells from bone marrow of breast cancer patients: Bidirectional cell stimulation, survival and antitumor activity in vivo

M. Feuerer, L. Bai, P. Beckhove, 2003, International journal of cancer.

42 – Bone health and prevention of treatment-induced osteoporosis in oncology

I. Diel, 2011 .

Brustkrebsnachsorge

I. Diel, 2008, Breast Care.

Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis

G. Bastert, G. Bastert, I. Diel, 2000, Breast Cancer Research and Treatment.

Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review

I. Diel, 2007, Supportive Care in Cancer.

What do patients with metastatic bone pain need

I. Diel, 2006 .

Management of Metastatic Bone Disease Algorithms for Diagnostics and Treatment.

K. Miller, I. Diel, A. Kurth, 2016, Anticancer research.

Treatment of bone metastasesin carcinoma of breast

I. Diel, E. Solomayer, C. Gollan, 1999, Der Gynäkologe.

Treatment of metastatic bone disease in breast cancer: bisphosphonates.

G. Bastert, I. Diel, E. Solomayer, 2000, Clinical breast cancer.

24 – Bisphosphonates and RANKL antibodies in breast carcinoma with bone metastases

I. Diel, 2011 .

Antitumour Effects of Bisphosphonates

I. Diel, 2000, Drugs.

Ibandronate: a well-tolerated intravenous and oral treatment for metastatic bone disease

I. Diel, 2004 .

Prognostic factors for skeletal relapse in breast cancer.

I. Diel, 2001, Cancer treatment reviews.

Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results

G. Mundy, I. Diel, 2000, British Journal of Cancer.

Systemic Treatment of Bone Metastases: Review of Literature and Retrospective Analysis of 718 Breast Cancer Patients

G. Bastert, S. Costa, G. Minckwitz, 1994 .

Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis.

G. Bastert, S. Costa, S. Costa, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bisphosphonates in Breast Cancer Patients with Bone Metastases

I. Diel, 2010, Breast Care.

Bisphosphonates in the prevention of bone metastases: current evidence.

I. Diel, 2001, Seminars in oncology.

Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin

H. Tesch, R. Baron, C. Maihöfner, 2021, Supportive Care in Cancer.

Ibandronate: efficacy in the treatment of metastatic bone disease.

I. Diel, 2005, Future oncology.

Bone metastases: Are we failing our patients?

B. Tombal, T. Brodowicz, I. Diel, 2014, Journal of bone oncology.

Concentration of insulin-like growth factor (IGF)-I and -II in iliac crest bone matrix from pre- and postmenopausal women: relationship to age, menopause, bone turnover, bone volume, and circulating IGFs.

R. Ziegler, J. Pfeilschifter, W. Blum, 1998, The Journal of clinical endocrinology and metabolism.

Transforming growth factor β (TGF-β) levels in the conditioned media of human bone cells: relationship to donor age, bone volume, and concentration of TGF-β in human bone matrix in vivo

R. Ziegler, J. Pfeilschifter, I. Diel, 1999 .

Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice

G. Bastert, M. Feuerer, H. Sinn, 2003, International journal of cancer.

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies

D. Tripathy, R. Bell, D. Tripathy, 2004, British Journal of Cancer.

Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 2 with Recommendations on Psycho-oncology, Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities.

M. Beckmann, S. Marnitz, T. Fehm, 2022, Geburtshilfe und Frauenheilkunde.

Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement.

R. Ziegler, J. Pfeilschifter, I. Diel, 1995, The Journal of clinical endocrinology and metabolism.

Concentrations of insulin-like growth factor (IGF)-I, -II, and IGF binding protein-4, and -5 in human bone cell conditioned medium do not change with age

S. Mohan, R. Ziegler, J. Pfeilschifter, 2000, Mechanisms of Ageing and Development.

11th International Conference St. Gallen: Primary Therapy of Early Breast Cancer

M. Beckmann, A. Schneeweiss, D. Wallwiener, 2009 .

L. Fallowfield, Y. Fujiwara, J. Jassem, 2012, Clinical Cancer Research.

Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study

R. Greil, I. Diel, A. Tomova, 2022, Supportive Care in Cancer.

Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

Y. Fujiwara, A. Stopeck, M. Carducci, 2015, Supportive Care in Cancer.

Ibandronate reduces skeletal morbidity in patients with breast cancer.

J. Body, I. Diel, Debu Tripathy A, 2004, Seminars in oncology.

Differences in Nephrotoxicity of Intravenous Bisphosphonates for the Treatment of Malignancy- Related Bone Disease

I. Diel, D. Henrich, M. Hoffmann, 2006, Oncology Research and Treatment.

Profiling the safety and tolerability of bisphosphonates.

R. Bell, J. Body, I. Diel, 2004, Seminars in oncology.

Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy

I. Diel, M. Pecherstorfer, 2004, Supportive Care in Cancer.

Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 1 with Recommendations on Epidemiology, Screening, Diagnostics and Therapy.

M. Beckmann, S. Marnitz, C. Hack, 2022, Geburtshilfe und Frauenheilkunde.

Re: Berenson J, Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid.

I. Diel, R. Bergner, 2005, The oncologist.

Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results.

D. Tripathy, J. Body, I. Diel, 2006, European journal of cancer care.

Monoclonal antibodies to detect breast cancer cells in bone marrow.

G. Bastert, S. Costa, M. Kaufmann, 1994, Important advances in oncology.

Analysis of sensitivity and specificity of cytokeratin 19 reverse transcriptase/polymerase chain reaction for detection of occult breast cancer in bone marrow and leukapheresis products

G. Bastert, X. Zhong, I. Diel, 1999, Journal of Cancer Research and Clinical Oncology.

Metastatic potential of small and minimally invasive breast carcinomas

H. Sinn, I. Diel, H. Anton, 2004, Virchows Archiv.

[The prognostic significance of tumor cell detection in bone marrow of patients with breast cancer].

G. Bastert, S. Costa, M. Kaufmann, 1990, Geburtshilfe und Frauenheilkunde.

Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study

R. Greil, I. Diel, A. Tomova, 2022, Supportive Care in Cancer.

Ibandronate: its role in metastatic breast cancer.

D. Cameron, M. Fallon, I. Diel, 2006, The oncologist.

Bisphosphonate zur Metastasenprävention: Die Metaanalyse der EBCTCG

I. Diel, 2016, Info Onkologie.

Transforming growth factor beta (TGF-beta) levels in the conditioned media of human bone cells: relationship to donor age, bone volume, and concentration of TGF-beta in human bone matrix in vivo.

R. Ziegler, J. Pfeilschifter, I. Diel, 1999, Bone.

Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow - a longtime follow-up

F. Schuetz, G. Bastert, S. Costa, 2004 .

56. Long-term follow-up of breast cancer patients with micrometastatic tumour cells in bone marrow at primary surgery — prognostic impact in comparison to nodal status

G. Bastert, S. Costa, M. Kaufmann, 1995 .

Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review

M. Neary, Jesse Green, N. Wintfeld, 2009, Supportive Care in Cancer.

Metastatic Bone Disease

G. Bastert, M. Kaufmann, I. Diel, 1994, Springer Berlin Heidelberg.

Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.

J. Kanis, P. Delmas, R. Kyle, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: Is there a diverse relationship of amino- and non-aminobisphosphonates?

M. Aapro, K. Väänänen, L. Pylkkänen, 2007, Critical reviews in oncology/hematology.

Expression of Interleukin-6 (IL-6) and IL-6 receptor mRNA in human bone samples from pre- and postmenopausal women.

R. Ziegler, J. Pfeilschifter, I. Diel, 2002, Bone.

Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples.

R. Ziegler, J. Pfeilschifter, I. Diel, 2001, European journal of endocrinology.

Concentration of Transforming Growth Factor Beta in Human Bone Tissue: Relationship to Age, Menopause, Bone Turnover, and Bone Volume

R Krempien, R. Krempien, J. Pfeilschifter, 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow

G. Bastert, M. Feuerer, L. Bai, 2001, Nature Medicine.

Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients

G. Bastert, M. Feuerer, L. Bai, 2001, International journal of cancer.

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

F. Saad, Lei Zhou, A. Stopeck, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate Treatment

A. Schneeweiss, M. Golatta, F. Schuetz, 2016, Annals of Surgical Oncology.

Reliable and sensitive analysis of occult bone marrow metastases using automated cellular imaging.

W. J. Decker, K. Bauer, B. Bossy, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

F. Saad, A. Stopeck, C. Barrios, 2012 .

Osteoporosis due to cancer treatment: pathogenesis and management.

J. Pfeilschifter, I. Diel, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer.

D. Wallwiener, G. Bastert, M. Kramer, 1997, British Journal of Cancer.

448 Alleviation of bone pain with oral and intravenous ibandronate in women with metastatic breast cancer

D. Tripathy, J. Body, I. Diel, 2003 .

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases.

M. Lichinitser, J. Body, E. Kreuser, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic relevance of cathepsin D detection in micrometastatic cells in the bone marrow of patients with primary breast cancer

D. Wallwiener, G. Bastert, I. Diel, 1998, Breast Cancer Research and Treatment.

Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors

Patrick M Liu, A. Lammerich, C. Abboud, 2018, Supportive Care in Cancer.

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019

M. Lux, P. Fasching, T. Fehm, 2019, Breast Care.

Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up.

F. Schuetz, C. Sohn, G. Bastert, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Age-associated changes in the stimulatory effect of transforming growth factor beta on human osteogenic colony formation

R. Ziegler, J. Pfeilschifter, I. Diel, 1999, Mechanisms of Ageing and Development.

NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis

H. Tesch, C. Salat, P. Klare, 2015, Oncology Research and Treatment.

Effect of 1-year intravenous ibandronate treatment on time to serum creatinine increase in patients with skeletal metastases from breast cancer.

D. Tripathy, J. Body, I. Diel, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy.

F. Schuetz, C. Sohn, G. Bastert, 2007, American journal of obstetrics and gynecology.

Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.

R. Holle, G. Bastert, G. von Minckwitz, 1996, Journal of the National Cancer Institute.

Time independence of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patients.

G. Bastert, G. Salanti, M. Hahn, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Interaction of psychosocial and physical risk factors in the causation of mammary cancer, and its prevention through psychological methods of treatment.

H. Eysenck, G. Boyle, I. Diel, 2000, Journal of clinical psychology.

Bone marrow staging for breast cancer: is it better than axillary node dissection?

I. Diel, 2001, Seminars in oncology.

[Significance of myoma-induced complications in pregnancy. A comparative analysis of pregnancy course with and without myoma involvement].

D. Wallwiener, B. Aydeniz, G. Bastert, 1998, Zeitschrift fur Geburtshilfe und Neonatologie.

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019

M. Lux, P. Fasching, T. Fehm, 2019, Breast Care.

Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer

R. Bell, D. Tripathy, J. Body, 2004, Pain.

S2-4: GAIN Study: A Phase III Trial To Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients with Node-Positive Primary Breast Cancer – 1st Interim Efficacy Analysis.

A. Schneeweiss, R. Kreienberg, S. Loibl, 2011 .

Influence of fluor salts, hormone replacement therapy and calcitonin on the concentration of insulin-like growth factor (IGF)-I, IGF-II and transforming growth factor-beta 1 in human iliac crest bone matrix from patients with primary osteoporosis.

R. Ziegler, J. Pfeilschifter, H. Minne, 2004, European journal of endocrinology.

Antitumour effects of bisphosphonates: first evidence and possible mechanisms.

I. Diel, 2000, Drugs.

Routine adjuvant use of bisphosphonates in breast cancer arguments in favour and against.

S. Aebi, I. Diel, 2010, Critical reviews in oncology/hematology.

The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.

A. Stopeck, G. Steger, F. Goldwasser, 2015, European journal of cancer.

Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany

I. Diel, H. Link, M. Kerkmann, 2019, Supportive Care in Cancer.

Surgical procedure can explain varying influence of menstrual cycle on prognosis of premenopausal breast cancer patients

M. Kaufmann, E. Grischke, G. Minckwitz, 1995 .

Long-Term Safety of Intravenous Ibandronic Acid for Up to 4 Years in Metastatic Breast Cancer

J. Body, I. Diel, B. Bergström, 2006, Clinical drug investigation.

Long-term (4-year) safety of intravenous Ibandronate in metastatic breast cancer: an open-label study

I. Diel, B. Bergström, M. Pecherstorfer, 2004 .

Results of iliac crest biopsies taken from 1465 patients with primary breast cancer

D. Wallwiener, G. Bastert, I. Diel, 1998, Journal of Cancer Research and Clinical Oncology.

Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany

M. Intorcia, I. Diel, D. Hohmann, 2020, Supportive Care in Cancer.

Bone pain reduction in patients with metastatic breast cancer treated with ibandronate–results from a post-marketing surveillance study

H. Meden, I. Diel, Andreas Sandermann, 2010, Supportive Care in Cancer.

Therapy of human tumors in NOD/SCID mice with patient derived re-activated memory T cells from bone marrow

G. Bastert, M. Feuerer, L. Bai, 2001 .

Long-term variability of bone turnover markers in patients with non-metastatic breast cancer.

M. Seibel, I. Diel, B. V. D. van der Velden, 2002, Clinical laboratory.

Renal safety of ibandronate in patients with bone metastases from breast cancer: phase III trial results

R. Bell, J. Body, I. Diel, 2004 .

Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer)

M. Beckmann, A. Schneeweiss, D. Wallwiener, 2009, Breast Care.

Interdisciplinary Consensus on the Use of Adjuvant Bisphosphonate Therapy in Breast Cancer Patients

T. Fehm, D. Wallwiener, M. Kaufmann, 2009 .

Incidence of osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases from solid tumors or multiple myeloma: Results from three phase III trials.

F. Saad, A. Stopeck, K. Tonkin, 2013 .

Clinical Recommendations of DEGRO and AGO on Preferred Standard Palliative Radiotherapy of Bone and Cerebral Metastases, Metastatic Spinal Cord Compression, and Leptomeningeal Carcinomatosis in Breast Cancer

T. Fehm, R. Souchon, C. Thomssen, 2010, Breast Care.

Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Primary Breast Cancer (Zurich 2011)

M. Beckmann, A. Schneeweiss, D. Wallwiener, 2011, Breast Care.

Erratum to: Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

Y. Fujiwara, A. Stopeck, M. Carducci, 2015, Supportive Care in Cancer.

AGO Recommendations for the Diagnosis and Therapy of Breast Cancer

M. Rezai, A. Schneeweiss, K. Friedrichs, 2007, Breast Care.

3051 POSTER Effect of Denosumab Treatment on Prevention of Hypercalcemia of Malignancy in Cancer Patients With Metastatic Bone Disease

A. Stopeck, G. Steger, F. Goldwasser, 2011 .

13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013).

M. Beckmann, T. Fehm, A. Schneeweiss, 2013, Breast care.

Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow - a longtime follow-up.

F. Schuetz, G. Bastert, S. Costa, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ibandronate: a well-tolerated intravenous and oral treatment for metastatic bone disease

I. Diel, 2004 .

Zurich Consensus: Statement of German Experts on St. Gallen Conference 2011 on Breast Cancer (Zurich 2011)

A. Schneeweiss, W. Eiermann, M. Kiechle, 2011 .